ABILIFY is an atypical antipsychotic indicated as oral formulations for the treatment of schizophrenia, bipolar disorder, major depressive disorder, and irritability associated with autistic disorder.
Traditional antipsychotics and the newer atypical antipsychotics are used in the treatment of schizophrenia and schizophrenia-related disorders and may also be used in the treatment of bipolar disorder, major depression, and autistic spectrum disorders.
Chlorpromazine hydrochloride is indicated for the treatment of psychotic disorders, of schizophrenia, of nausea and vomiting, of restlessness and apprehension before surgery, of manic episodes, of intractable hiccups, and of severe behavioral problems in children.
Clozaril® (clozapine), an atypical antipsychotic drug, is a tricyclic dibenzodiazepine derivative, indicated for the management of severely ill schizophrenic patients who fail to respond adequately to standard drug treatment for schizophrenia.
Fanapt® tablets are indicated for the treatment of adults with schizophrenia. The effectiveness of FANAPT in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials.
Fluphenazine hydrochloride is a trifluoromethyl phenothiazine derivative intended for the management of schizophrenia. Fluphenazine HCl has not been shown effective in the management of behavioral complications in patients with mental retardation.
GEODON is indicated for the treatment of schizophrenia, as monotherapy for the acute treatment of bipolar manic or mixed episodes, and as an adjunct to lithium or valproate for the maintenance treatment of bipolar disorder.
Haloperidol is the first of the butyrophenone series of major antipsychotics. Haldol (haloperidol) is indicated for use in the treatment of schizophrenia and for the control of tics and vocal utterances of Tourette’s Disorder.